Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors-Reference-Cited by-同舟云学术

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors

Published:2017-08-03 Issue:8 Volume:12 Page:e0182665
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Arbour Kathryn C.^ORCID,Naidoo Jarushka,Steele Keith E.,Ni Ai,Moreira Andre L.,Rekhtman Natasha,Robbins Paul B.,Karakunnel Joyson,Rimner Andreas,Huang James,Riely Gregory J.,Hellmann Matthew D.

Funder

National Cancer Institute

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference29 articles.

1. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification;WD Travis;J Thorac Oncol,2015

2. Thymoma associated with autoimmune diseases: 85 cases and literature review;C Bernard;Autoimmun Rev,2016

3. Clinical Characteristics and Outcomes for Patients with Thymic Carcinoma: Evaluation of Masaoka Staging;AM Litvak;J Thorac Oncol Off Publ Int Assoc Study Lung Cancer,2014

4. Phase II Study of Carboplatin and Paclitaxel in Advanced Thymoma and Thymic Carcinoma;GL Lemma;J Clin Oncol,2011

5. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial;PJ Loehrer;J Clin Oncol,1997

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolving treatment landscape in thymic epithelial tumors: From mechanism to therapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Case report: A sustained survival benefit of third-line immunotherapy for refractory thymic carcinoma;Frontiers in Oncology;2024-07-23

3. Immunotherapy in thymic epithelial tumors: tissue predictive biomarkers for immune checkpoint inhibitors;Exploration of Targeted Anti-tumor Therapy;2024-05-21

4. Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs;Frontiers in Immunology;2024-04-02

5. PD-L1 Expression in Neoplastic and Immune Cells of Thymic Epithelial Tumors: Correlations with Disease Characteristics and HDAC Expression;Biomedicines;2024-03-31